An Exploratory Study of Adjuvant Therapy of Pegylated Interferon-Alfa 2b Plus Melanoma Peptide Vaccine in Patients With Resected Stage II and III (N1a, N2a) Melanoma
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Melanoma vaccine gp100 (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- 28 Feb 2017 Status changed from active, no longer recruiting to completed.
- 25 Apr 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 25 Apr 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.